Literature DB >> 9220410

Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study.

M Bendini1, C Zuiani, M Bazzocchi, G Dalpiaz, F Zaja, E Englaro.   

Abstract

PURPOSE: To assess the potential value of magnetic resonance imaging (MRI) combined with 67Ga single-photon emission computed tomography (SPECT) versus computed tomography (CT) in the staging and in the monitoring of mediastinal malignant lymphoma.
MATERIALS AND METHODS: Twenty-three patients, referred to our institute for the evaluation of lymphoma, underwent CT, 67Ga scan, and MRI between April 1993 and February 1996 at sequential intervals. The tests studied (MRI, 67Ga, and CT) were performed according to the following schedule: 1) before start of therapy; 2) after four courses of chemotherapy; and 3) 2, 6, 12, and 18 months after the end of treatment.
RESULTS: All patients studied at the time of diagnosis had abnormal gallium accumulation in the mediastinum as well as pathologic CT and pathologic signal intensity at MRI. Six months after the end of treatment full consistency was found between the results of MRI and SPECT, whereas during treatment and 2 months after the end of therapy MRI and 67Ga scan were not in agreement in nine patients. In the 23 patients in follow-up, in CT there were nine false-positive and three false-negative findings; in SPECT three false negatives; in MRI one false positive and one false negative.
CONCLUSION: MRI can give morphologic information similar to CT, even superior due to multiplanarity and with major precision in the distinction between fibrosis and active disease. MRI is thus an alternative to CT. The association with SPECT allows a great diagnostic accuracy in the positive and negative predictive value.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9220410     DOI: 10.1007/bf01772009

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  27 in total

1.  Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging.

Authors:  R S Nyman; S M Rehn; B L Glimelius; H E Hagberg; A L Hemmingsson; C J Sundström
Journal:  Radiology       Date:  1989-02       Impact factor: 11.105

2.  Gallium 67 citrate scanning in patients with pulmonary sarcoidosis.

Authors:  A Heshiki; S L Schatz; K A McKusick; D W Bowersox; J S Soin; H N Wagner
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1974-12

Review 3.  Hodgkin disease: practical concepts for the diagnostic radiologist.

Authors:  R A Castellino
Journal:  Radiology       Date:  1986-05       Impact factor: 11.105

4.  Comparison of initial lymphoma staging using computed tomography (CT) and magnetic resonance (MR) imaging.

Authors:  B R Hoane; A F Shields; B A Porter; J W Borrow
Journal:  Am J Hematol       Date:  1994-10       Impact factor: 10.047

5.  Post-therapy CT-detected mass in lymphoma patients: is it viable tissue?

Authors:  E Lewis; M E Bernardino; P G Salvador; F F Cabanillas; P A Barnes; J L Thomas
Journal:  J Comput Assist Tomogr       Date:  1982-08       Impact factor: 1.826

6.  Regression of mediastinal Hodgkin disease after therapy: evaluation of time interval.

Authors:  L B North; L M Fuller; J A Sullivan-Halley; F B Hagemeister
Journal:  Radiology       Date:  1987-09       Impact factor: 11.105

7.  Lymphoma of the mediastinum and neck: evaluation with Ga-67 imaging and CT correlation.

Authors:  S R Drossman; R G Schiff; G D Kronfeld; J McNamara; J C Leonidas
Journal:  Radiology       Date:  1990-01       Impact factor: 11.105

Review 8.  The role of gallium-67 in the clinical evaluation of cancer.

Authors:  C Bekerman; P B Hoffer; J D Bitran
Journal:  Semin Nucl Med       Date:  1984-10       Impact factor: 4.446

9.  Current role of gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma.

Authors:  M D Gasparini; L Balzarini; M R Castellani; J D Tesoro Tess; L S Maffioli; R Petrillo; E Ceglia; R Musumeci; G L Buraggi
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

10.  Radiation fibrosis: differentiation from recurrent tumor by MR imaging.

Authors:  H S Glazer; J K Lee; R G Levitt; J P Heiken; D Ling; W G Totty; D M Balfe; B Emani; T H Wasserman; W A Murphy
Journal:  Radiology       Date:  1985-09       Impact factor: 11.105

View more
  3 in total

Review 1.  Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives.

Authors:  D Visvikis; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-13       Impact factor: 9.236

2.  [Importance of PET/CT in lymphoma diagnostics].

Authors:  A Afshar-Oromieh; C Kratochwil; U Haberkorn; F L Giesel
Journal:  Radiologe       Date:  2012-04       Impact factor: 0.635

Review 3.  PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  Christiaan Schiepers; Jean-Emmanuel Filmont; Johannes Czernin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-26       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.